{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.53","upperLimit":"2.08","value":"1.510"},{"groupId":"OG001","lowerLimit":"0.50","upperLimit":"4.10","value":"1.150"},{"groupId":"OG002","lowerLimit":"0.50","upperLimit":"23.80","value":"1.500"},{"groupId":"OG003","lowerLimit":"1.00","upperLimit":"8.00","value":"1.500"},{"groupId":"OG004","lowerLimit":"1.50","upperLimit":"2.07","value":"2.050"},{"groupId":"OG005","lowerLimit":"0.50","upperLimit":"4.00","value":"1.540"},{"groupId":"OG006","lowerLimit":"0.52","upperLimit":"8.03","value":"1.500"},{"groupId":"OG007","lowerLimit":"0.50","upperLimit":"4.17","value":"2.000"},{"groupId":"OG008","lowerLimit":"0.43","upperLimit":"8.05","value":"2.000"},{"groupId":"OG009","lowerLimit":"0.95","upperLimit":"4.00","value":"1.500"}]}],"title":"Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","upperLimit":"2.00","value":"1.265"},{"groupId":"OG001","lowerLimit":"0.53","upperLimit":"3.00","value":"1.750"},{"groupId":"OG002","lowerLimit":"1.00","upperLimit":"8.13","value":"1.970"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG005","lowerLimit":"1.50","upperLimit":"8.00","value":"1.550"},{"groupId":"OG006","lowerLimit":"0.52","upperLimit":"7.98","value":"2.030"},{"groupId":"OG007","lowerLimit":"0.92","upperLimit":"8.00","value":"1.530"},{"groupId":"OG008","lowerLimit":"0.50","upperLimit":"8.00","value":"1.750"},{"groupId":"OG009","lowerLimit":"0.50","upperLimit":"3.97","value":"1.050"}]}],"title":"Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"description":"The time to reach maximum plasma concentration (Tmax) of SAR245409 was calculated.","dispersionType":"Full Range","groups":[{"description":"SAR245409 capsule administered at a single oral dose of 30 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG000","title":"SAR245409 30mg"},{"description":"SAR245409 capsule administered at a single oral dose of 50 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG001","title":"SAR245409 50mg"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG002","title":"SAR245409 70mg"},{"description":"SAR245409 capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG003","title":"SAR245409 90mg"},{"description":"SAR245409 capsule administered twice, orally, at a dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG004","title":"SAR245409 30mg Twice Daily"},{"description":"SAR245409 capsule administered twice, orally, at a dose of 50 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG005","title":"SAR245409 50mg Twice Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: SAR245409 70mg Once Daily"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set. Here \"n\" signifies the number of subjects evaluable at the specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Time to Reach Maximum Plasma Concentration (Tmax) of SAR245409","type":"SECONDARY","unitOfMeasure":"hours"}